Day: May 11, 2023

SALINAS, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (“Lowell Farms” or the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born vertically integrated cannabis company with advanced production capabilities including cultivation, extraction, manufacturing, and distribution, announces unaudited revenue and operating results for the first quarter of 2023 (ended March 31, 2023). All figures stated are in US Dollars. First Quarter Financial Highlights Revenues:       Net revenue generated for Q1 2023 decreased 39% to $7.5 million, as compared to $12.4 million for Q1 2022. Net revenue was $9.3 million for Q4 2022, a decrease of 19%.CPG revenue decreased 49% compared to Q1 2022, and decreased 18% compared to Q4 2022. Bulk revenue from self-grown wholesale products increased 44% compared to Q1 2022 and decreased 9%...

CALGARY, Alberta, May 11, 2023 (GLOBE NEWSWIRE) — Cardinal Energy Ltd. (“Cardinal” or the “Company”) (TSX: CJ) is pleased to announce its operating and financial results for the first quarter ended March 31, 2023. FINANCIAL AND OPERATING HIGHLIGHTS FROM THE FIRST QUARTER OF 2023Production increased 5% over the same period in 2022 due to ongoing strong base performance and excellent 2022 drilling results across our asset base;Adjusted funds flow(1) was $52.3 million which was allocated to capital expenditures(1) of $25.3 million and dividends of $28.7 million;Cardinal’s net debt(1) has decreased by 47% in the last 12 months closing at $78 million at March 31, 2023;Achieved a net debt to adjusted funds flow ratio(1) of 0.2x for the first quarter of 2023;In the last 12 months, Cardinal has...

CALGARY, Alberta, May 11, 2023 (GLOBE NEWSWIRE) — TSX-V: CWV: Crown Point Energy Inc. (“Crown Point”, the “Company” or “we“) today announced its operating and financial results for the three months ended March 31, 2023. Copies of the Company’s March 31, 2023 unaudited condensed interim consolidated financial statements and management’s discussion and analysis (“MD&A”) filings are being filed with Canadian securities regulatory authorities and will be made available under the Company’s profile at www.sedar.com and on the Company’s website at www.crownpointenergy.com. All dollar figures are expressed in United States dollars (“USD”) unless otherwise stated. References to “ARS” are to Argentina Pesos. In the following discussion, the three months ended March 31, 2023 may be referred to as “Q1...

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline. “The recently received $20.0 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYOTM (rezafungin for injection) further strengthened our balance sheet,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Importantly, we remain eligible to receive additional non-dilutive capital of up to approximately $47.1 million in development and regulatory milestones...

TORONTO, May 11, 2023 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the first quarter of 2023. David Clare, President and CEO of Trisura, stated, “Trisura reported strong performance in the quarter with operating net income of $28.6 million, or $0.61 per share. Quarterly net income of $14.0 million, or $0.30 per share, was impacted both by the implementation of new IFRS standards and the run-off of a US program. Expansion of distribution relationships and maturation of our platform drove increased market share and resulted in insurance revenue growth of 58.3%. In Canada, disciplined underwriting yielded a combined ratio of 80.7%. Our US fronting business produced $459.3 million of insurance revenue and reported deferred...

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official Cash, cash equivalents and marketable securities of $286.5 million with runway through the end of 2024SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the first quarter ended March 31, 2023. “We continue to achieve multiple significant milestones,...

Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 PITTSBURGH, May 11, 2023 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments. “To date in 2023, we have made steady progress advancing the development of our gene editing application based on our PATrOL™ platform. One of the main drivers behind the initial success of this application...

Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 data Initiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonist Reiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 millionSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter...

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first several months of 2023, we continued making progress to align with the FDA on an efficient development pathway to support registration of TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes and we remain on-track to commence study activities in the second half of the year,” said Paul Sekhri, Chief Executive Officer of vTv. “In addition to our ongoing efforts to advance studies of TTP399 in type 1 diabetes,...